ArticleJACC. Advances2026
SGLT2 Inhibitors and Mortality in Endometriosis With Type 2 Diabetes: A Propensity-Matched Analysis.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometriosis is increasingly recognized as a systemic inflammatory condition associated with adverse cardiovascular events, yet glucose-lowering drug selection in this population is not evidence-based.
objectivesThe purpose of this study was to compare mortality, cardiovascular outcomes, and renal endpoints among adults with endometriosis and type 2 diabetes (T2D) treated with sodium glucose co-transporter 2 inhibitors (SGLT2i) added to background metformin therapy vs metformin-based therapy without SGLT2i.
methodsWe conducted a retrospective cohort study using routinely collected health data. Adults with endometriosis and T2D initiating SGLT2i or receiving metformin-based therapy were identified, and 1:1 propensity score matching was performed. After matching, there were 3,072 patients in each group. The mean follow-up was 2.8 ±1.8 years (median, 2.8; IQR: 3.7). Outcomes were analyzed with time-to-event models and reported as HRs with 95% CIs.
resultsIn the matched cohort (n = 6,144), all-cause mortality was lower with SGLT2i added to metformin vs metformin-based therapy without SGLT2i (55 vs 115 deaths; 0.65% vs 1.15% per year; HR: 0.52 [95% CI: 0.38-0.72]; P < 0.0001). Rates of ischemic stroke/thromboembolism, acute myocardial infarction, atrial fibrillation, ventricular arrhythmia/cardiac arrest, heart failure, acute pulmonary edema/cardiogenic shock, and peripheral artery disease were not significantly different. Progression to chronic kidney disease stage 4 to 5 was numerically higher with SGLT2i (HR: 1.28 [95% CI: 0.99-1.64]; P = 0.05).
conclusionsIn a propensity-matched analysis of patients with endometriosis and T2D, use of SGLT2i on top of background metformin therapy was associated with lower mortality compared with metformin-based therapy without SGLT2i, with no significant differences in most cardiovascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.